ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) Stock Fundamental Analysis
OSL:AZT - Euronext Oslo - NO0010014632 - Common Stock - Currency: NOK
Overall AZT gets a fundamental rating of 5 out of 10. We evaluated AZT against 73 industry peers in the Biotechnology industry. Both the profitability and the financial health of AZT get a neutral evaluation. Nothing too spectacular is happening here. AZT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AZT had positive earnings in the past year.
In the past year AZT had a positive cash flow from operations.
AZT had positive earnings in each of the past 5 years.
AZT had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AZT (0.64%) is better than 69.86% of its industry peers.
The Return On Equity of AZT (0.68%) is better than 72.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.64% | ||
| ROE | 0.68% | ||
| ROIC | N/A |
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AZT's Profit Margin of 2.25% is fine compared to the rest of the industry. AZT outperforms 75.34% of its industry peers.
In the last couple of years the Profit Margin of AZT has declined.
With an excellent Gross Margin value of 94.33%, AZT belongs to the best of the industry, outperforming 93.15% of the companies in the same industry.
In the last couple of years the Gross Margin of AZT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.25% | ||
| GM | 94.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
2. Health
2.1 Basic Checks
AZT does not have a ROIC to compare to the WACC, probably because it is not profitable.
AZT has more shares outstanding than it did 1 year ago.
AZT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AZT has been reduced compared to a year ago.
2.2 Solvency
AZT has an Altman-Z score of 25.21. This indicates that AZT is financially healthy and has little risk of bankruptcy at the moment.
AZT's Altman-Z score of 25.21 is amongst the best of the industry. AZT outperforms 95.89% of its industry peers.
AZT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AZT (0.02) is better than 75.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 25.21 |
ROIC/WACCN/A
WACC8.47%
2.3 Liquidity
A Current Ratio of 17.49 indicates that AZT has no problem at all paying its short term obligations.
With an excellent Current ratio value of 17.49, AZT belongs to the best of the industry, outperforming 98.63% of the companies in the same industry.
AZT has a Quick Ratio of 16.53. This indicates that AZT is financially healthy and has no problem in meeting its short term obligations.
AZT's Quick ratio of 16.53 is amongst the best of the industry. AZT outperforms 98.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.49 | ||
| Quick Ratio | 16.53 |
3. Growth
3.1 Past
AZT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -93.94%.
Measured over the past years, AZT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -43.42% on average per year.
The Revenue for AZT has decreased by -17.09% in the past year. This is quite bad
Measured over the past years, AZT shows a quite strong growth in Revenue. The Revenue has been growing by 18.22% on average per year.
EPS 1Y (TTM)-93.94%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-17.09%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%-22.45%
3.2 Future
AZT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 63.87% yearly.
AZT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.65% yearly.
EPS Next Y26.25%
EPS Next 2Y69.87%
EPS Next 3Y63.87%
EPS Next 5YN/A
Revenue Next Year8.45%
Revenue Next 2Y14.04%
Revenue Next 3Y15.71%
Revenue Next 5Y30.65%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 810.00, which means the current valuation is very expensive for AZT.
Based on the Price/Earnings ratio, AZT is valued a bit cheaper than 73.97% of the companies in the same industry.
AZT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.34.
The Price/Forward Earnings ratio is 40.10, which means the current valuation is very expensive for AZT.
Based on the Price/Forward Earnings ratio, AZT is valued a bit cheaper than the industry average as 79.45% of the companies are valued more expensively.
AZT is valuated expensively when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 810 | ||
| Fwd PE | 40.1 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AZT does not grow enough to justify the current Price/Earnings ratio.
AZT's earnings are expected to grow with 63.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)30.86
PEG (5Y)N/A
EPS Next 2Y69.87%
EPS Next 3Y63.87%
5. Dividend
5.1 Amount
No dividends for AZT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:AZT (6/19/2025, 3:41:07 PM)
16.2
-0.3 (-1.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.83%
Inst Owner ChangeN/A
Ins Owners0.35%
Ins Owner ChangeN/A
Market Cap827.33M
Analysts76.67
Price Target18.36 (13.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)509.19%
Min EPS beat(2)-269.73%
Max EPS beat(2)1288.12%
EPS beat(4)1
Avg EPS beat(4)208.45%
Min EPS beat(4)-269.73%
Max EPS beat(4)1288.12%
EPS beat(8)3
Avg EPS beat(8)114.16%
EPS beat(12)3
Avg EPS beat(12)63.08%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-13.1%
Max Revenue beat(2)2.64%
Revenue beat(4)1
Avg Revenue beat(4)-10.13%
Min Revenue beat(4)-18.99%
Max Revenue beat(4)2.64%
Revenue beat(8)2
Avg Revenue beat(8)-7.15%
Revenue beat(12)2
Avg Revenue beat(12)-7.23%
Revenue beat(16)5
Avg Revenue beat(16)-4.68%
PT rev (1m)-5.26%
PT rev (3m)-5.26%
EPS NQ rev (1m)-7.69%
EPS NQ rev (3m)-7.69%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.22%
Revenue NQ rev (1m)-8.77%
Revenue NQ rev (3m)-8.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 810 | ||
| Fwd PE | 40.1 | ||
| P/S | 8.48 | ||
| P/FCF | N/A | ||
| P/OCF | 154.41 | ||
| P/B | 2.57 | ||
| P/tB | 2.86 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.02
EY0.12%
EPS(NY)0.4
Fwd EY2.49%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.1
OCFY0.65%
SpS1.91
BVpS6.31
TBVpS5.66
PEG (NY)30.86
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.64% | ||
| ROE | 0.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2.25% | ||
| GM | 94.33% | ||
| FCFM | N/A |
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
F-Score5
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 80.55% | ||
| Cap/Sales | 6.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.49 | ||
| Quick Ratio | 16.53 | ||
| Altman-Z | 25.21 |
F-Score5
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)231.16%
Cap/Depr(5y)215.23%
Cap/Sales(3y)11.45%
Cap/Sales(5y)9.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.94%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y26.25%
EPS Next 2Y69.87%
EPS Next 3Y63.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-17.09%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%-22.45%
Revenue Next Year8.45%
Revenue Next 2Y14.04%
Revenue Next 3Y15.71%
Revenue Next 5Y30.65%
EBIT growth 1Y-168.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year342.86%
EBIT Next 3Y124.31%
EBIT Next 5YN/A
FCF growth 1Y-102.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-84.71%
OCF growth 3Y-71.92%
OCF growth 5Y-16%